Bill > S2093

This bill, the Disease X Act of 2023, establishes a program at the Biomedical Advanced Research and Development Authority (BARDA) to develop medical countermeasures for viral threats with pandemic potential. The key provisions of the bill include authorizing additional funding of $40 million annually from 2024 to 2028 to be used specifically for identifying and developing platform manufacturing technologies, as well as advanced research and development of flexible medical countermeasures against priority respiratory virus families and other viral pathogens with significant pandemic potential. The bill also requires that any products developed using this additional funding be substantially manufactured in the United States, though the Secretary may waive this requirement if it is determined to be inconsistent with the public interest.

Health and Social Services

https://www.congress.gov/bill/118th-congress/senate-bill/2093/all-info